资源描述：
《伐地那非对急性肺血栓栓塞症家兔的治疗效果研究.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、伐地那非对急性肺血栓栓塞症家兔的治疗效果研究［摘要］目的探讨伐地那非治疗急性肺血栓栓塞症(APTE)的疗效及可行性。方法选用日木大耳纯种家兔36只，随机分为4组，每组9只，分别为空白对照组、APTE模型组、伐地那非低剂量组、伐地那非高剂量组。对家兔进行急性肺血栓栓塞症造模，APTE组无药物干预；伐地那非低剂量组：予伐地那非片1.5mg/kg治疗；伐地那非高剂量组：予伐地那非片3.0mg/kg治疗。测定家兔栓塞后各时间点(0h,1h,2h,4h)的动脉血气、肌钙蛋白(cTnT)、N端前脑钠肽(NT-proBNP)、右室收缩压(RVSP)
2、、平均动脉压(MAP)并比较各组数据。结果APTE模型组与伐地那非低、高剂量组检验结果差异均具有统计学意义(P<0.05)；伐地那非低、高剂量组检验结果差异具有统计学意义(P<0.05)o结论伐地那非可改善急性肺血栓栓塞家兔的动脉血气、NT-proBNP、cTnl及血流动力学指标，对肺栓寒W一定的治疗效果。［关键词］急性肺血栓栓塞；5型磷酸二酯酶抑制剂；伐地那非［中图分类号］R563.5［文献标识码］A［文章编号］1673-9701(2013)25-0010-04Therapiceffectresearchonvardenafilfo
3、racutepulmonarythromboembolismrabbitsCIIENZhiliMIAOXinjunCHENYuxiDepartmentofEmergency,WenzhouCentralHospitalinZhejiangProvince,Wenzhou325000,China[Abstract]ObjectiveToinvestigatethetherapiceffectandfeasibilityofvardenafilinthetreatmentofacutepulmonarythromboembolism（A卩
4、TE）•MethodsAtotalof36Japanlargeearpurebredrabbitswererandomlydividedinto4groups,respectivelyforthecontrolgroup,theAPTEmodelgroup,thelow-dosevardenafilgroup,thehigh-dosevardenafilgroup,andeachgrouphad9rabbits・TheAPTEmodelofrabbitsweremade.TheAPTEmodelgroupweregivennon-dr
5、ugintervention,whi1ethe1ow-dosevardenafilgroupweregiven1.5mg/kgvardenafiltreatment,andthehigh-dosevardenafilgroupweregiven3.0mg/kgvardenafiltreatment・Thearterialbloodgas,cardiactroponinI（cTnl）,N-terininalproB~typenatriureticpeptide（NT-proBNP）,rightventricularsystolicpre
6、ssure（RVSP）,meanarterialpressure（MA卩）ofrabbitsat0h,1h,2hand4haftertransarterialchemoembo1izationweredeterminedandcompared.ResultsThedifferenceswerestatisticallysignificantinexaminationresultsamongtheAPTEmodelgroup,thelow-dosevardenafilgroupandthehigh-dosevardenafilgroup
7、（卩〈0.05）•Thereweresignificantdifferencesinexaminationresultsbetweenthelow-dosevardenafilgroupandthehigh-dosevardenafilgroup（P〈0.05）.ConclusionVardenafilcanimprovethearterialbloodgas,NT-proBNP,cTnTandhemodynamicsindexesofacutepulmonarythromboembolismrabbits,andhassomethe
8、rapiceffectforpulmonaryembolism.[Keywords]Acutepulmonarythromboembolism；Type~5phosphodiesteraseinhibitor；Varde
